Form 8-K - Current report:
SEC Accession No. 0001193125-19-289316
Filing Date
2019-11-12
Accepted
2019-11-12 08:06:40
Documents
14
Period of Report
2019-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d829282d8k.htm   iXBRL 8-K 27734
2 EX-99.1 d829282dex991.htm EX-99.1 80417
6 GRAPHIC g829282g1109051354505.jpg GRAPHIC 3241
  Complete submission text file 0001193125-19-289316.txt   243354

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA urgn-20191112.xsd EX-101.SCH 3065
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20191112_lab.xml EX-101.LAB 17375
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20191112_pre.xml EX-101.PRE 10950
12 EXTRACTED XBRL INSTANCE DOCUMENT d829282d8k_htm.xml XML 3232
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 191206262
SIC: 2834 Pharmaceutical Preparations